Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vitamin B12
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Injectable Vs Oral Vitamin Combination
Details : Vitamin B12 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Vitamin B 12 Deficiency.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 19, 2025
Lead Product(s) : Vitamin B12
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vadadustat
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Recipient : Erkim
Deal Size : Undisclosed
Deal Type : Agreement
Er-Kim Announces Distribution Agreement with MEDICE for Vafseo® in Europe
Details : Under the agreement, Er-Kim partner with the MEDICE to commercialize the Vafseo (vadadustat). It is being indicated for the treatment of of symptomatic anaemia associated with CKD in adults.
Product Name : Vafseo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 14, 2025
Lead Product(s) : Vadadustat
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Recipient : Erkim
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Restharrow Root Extract
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Dr. Wiedey GmbH - Institut Für Klinische Forschung | Medidata Dr Möller
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Restharrow Root Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 25, 2019
Lead Product(s) : Restharrow Root Extract
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Dr. Wiedey GmbH - Institut Für Klinische Forschung | Medidata Dr Möller
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Benzalkonium Chloride-Benzocaine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : University Hospital Muenster
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of a Sore Throat Lozenge DORITHRICIN in Patients With Acute Pharyngitis
Details : Benzalkonium Chloride-Benzocaine is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pharyngitis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 27, 2017
Lead Product(s) : Benzalkonium Chloride-Benzocaine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : University Hospital Muenster
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Bicarbonate
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : Prim. Priv. Doz. Dr. Daniel Cejka
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sodium Bicarbonate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft Rejection.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 04, 2017
Lead Product(s) : Sodium Bicarbonate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : Prim. Priv. Doz. Dr. Daniel Cejka
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicotinamide in Hemodialysis Patients With Hyperphosphatemia
Details : Nicotinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2010
Lead Product(s) : Nicotinamide
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
